Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  bleomycin sulfate
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment
Age: 18 and younger
Trial IDs: AHOD1331, NCI-2014-01223, NCT02166463
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 0 to 49
Trial IDs: AGCT1531, NCI-2017-00178, NCT03067181
Combination Chemotherapy with or without Radiation Therapy in Treating Young Patients with Favorable-Risk Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HOD08, NCI-2009-01138, NCT00846742
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients with Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GOG-0264, NCI-2011-02000, CDR0000662814, NCT01042522
Response-Based Therapy Assessed by PET Scan in Treating Patients with Stage IA-IIB Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 to 60
Trial IDs: CALGB-50801, NCI-2011-02034, CDR0000669076, NCT01118026
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low or Intermediate-Risk Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: H-30993, NCI-2013-01346, TXCH-HD-12A, NCT01858922
Nivolumab and Combination Chemotherapy in Treating Patients with Untreated Stage III-IV Classical Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-1536, NCI-2017-00334, NCT03033914
Start Over